8,883 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Five Oceans Advisors

Five Oceans Advisors bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 8,883 shares of the biopharmaceutical company’s stock, valued at approximately $225,000.

Several other large investors also recently made changes to their positions in the company. Bell Bank boosted its position in Pfizer by 10.5% during the 1st quarter. Bell Bank now owns 366,542 shares of the biopharmaceutical company’s stock worth $9,288,000 after acquiring an additional 34,740 shares during the period. PKO Investment Management Joint Stock Co grew its position in Pfizer by 19.0% in the 1st quarter. PKO Investment Management Joint Stock Co now owns 94,000 shares of the biopharmaceutical company’s stock valued at $2,382,000 after buying an additional 15,000 shares in the last quarter. Bfsg LLC increased its stake in Pfizer by 1.4% during the 1st quarter. Bfsg LLC now owns 184,709 shares of the biopharmaceutical company’s stock valued at $4,681,000 after buying an additional 2,514 shares during the period. Cardinal Capital Management raised its position in shares of Pfizer by 5.7% during the 1st quarter. Cardinal Capital Management now owns 95,064 shares of the biopharmaceutical company’s stock worth $2,409,000 after buying an additional 5,149 shares in the last quarter. Finally, Chicago Capital LLC lifted its stake in shares of Pfizer by 38.8% in the 1st quarter. Chicago Capital LLC now owns 97,375 shares of the biopharmaceutical company’s stock worth $2,467,000 after acquiring an additional 27,206 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.6%

Shares of NYSE PFE opened at $24.40 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The business has a 50-day moving average price of $23.11 and a two-hundred day moving average price of $24.93. The firm has a market capitalization of $138.71 billion, a PE ratio of 17.30, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.82 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.05%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Analyst Ratings Changes

Several equities research analysts recently commented on PFE shares. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.